Background and Objectives: Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) is a limb salvage therapy for non-resectable soft tissue sarcomas (STS) of the extremilies. Il is indicated for patients for whom amputation or debilitating surgery is the only alternative. lt can be uscd cither as an exclusive thcrapy (in palliation) or as a nco-adjuvant trcatmcnt. followed by marginal resection of turnor remnants with minimal functional impairment. Methods: Between February ll)')2 and March 2006, 57 TM-ILPs were perfonned on 5 l patients wilh 881)1, high grade and 84% advanced stage tumors.
Results: Mean follow-up is 38.9 months (4-159, rnedian 22 months). Twenty-one percent patients had significant early complications, with 3 major re-operations, imd 23%> suffered long-lasting complications. Cornplele response was observed in 25%, partial response in 42%, slable discase in 14% and progressive discasc in l4%. Rcscetion of the tumor remnants was possible in 65%. A eornplcmentary trcatrnent was ncccssary in 31 %, mostly radü1tion thernpy. A local recurrence was observed in 35%, after a mean of 20.3 months (2-78). and distant relapse was seen in 45%. after a mean of l3.4 months . Mean Disease-free survival was 14.9 months, and overall 5-year-survival 43.5%. Amputation rate al 5 ycars was 24%. Conclusions: TM-ILP is a conservative treatment with a high complications rate, but it can be successful even for the most severe STS of extremities. As a consequence the lirnb can be spared frmn amputation or debilitating surgery on the long terrn in about 75% of patients .
INTRODUCTION
Soft tissue sarcomas (STS) account for approximately 1 % of ail newly diagnosed lumors; over 50% arise in the extremities [ 1.2] . Limbsparing surgery, generally associated with radiation therapy, can be successfully pe1formed in up to 90% of these tumors, whereas amputation was the rule in nearly 50% hefore the l980s [3] [4] [5] . Moreovcr, it has been proven that amputation docs not improve ovcrall survival, especially for large deep-seated high grade tumors [6] [7] [8] [9] . Treatment of the latter is challenging, because of the size and location that often makes a surgical extirpation difficult or impossible without severe functional impairment. Multiple strategies have been cleveloped to improve limb salvage, comprising radiation therapy, chemotherapy (intra-arterial or systemic ), or both, delivercd pre-or post-opcrativcly [10] [11] [12] [13] [14] [15] .
Isolated limb perfusion (ILP) consists in surgically isolating the affectcd extremity by cannulating its vesscls and connccting them to a hemt-lung machine. A tourniquet is then applied at the root of the limb and an extra-corporeal circulation is achieved in mild hyperthermia. Drugs can be pcrfused in concentrations up to 30-fold the levcl tolerated in systemic infusion [16] . Leakage is monitored with better results were obtained wilh the combination of high dose tmnor necrosis factor-alpha (TNF-alpha) with melphalan. a low regional toxicity alkylating agent, first rep01ted in 1992 [22] . Severa! multicenter and institutional studies confirmed the high el1icacy of TNF and melphalan-ILP (TM-ILP). Completc responsc (CR) rates ncar 100% were obtained for melanomas and objective response rates as high as 80-90% were reported for non-resectable STS, with CR between 28% and 70%, and limb salvage reaehing 81-90% [23] [24] [25] [26] [27] . Inte1feron gamma was initially added for its synergy with TNF-alpha. but was then abandoned for it did not prove to give significant better rcsults than the double association in TM-ILP [23] .
The mcchanism whcreby TNF-alpha works has been pmtially deciphered (reviewed in Ref. [28] ): in the early phase (within minutes), it improves penetration of anticanccr agents in cancer cells by enhancing permcability of nco-cndothclial ce lis and pcricytcs. In the second phase (days). it induces destrnction of neo-angiogenic vessels by apoptosis of the cndothelial cclls. and intravascular thrombocytes aggregation by local procoaguhmt activity.
Over time, different drugs (cisplatin, doxorubicin, etc.) and conditions have bcen expe1ienccd (truc hypcrthennia, hypoxia, varying duration of perfusion) to improve the efficiency of ILP. never reaching as high response rates with such a low toxicity profile as with TNFalpha and melphalan in rnild hyperthermia (<40°) for 90 min [29, 30] .
Our center actively participnted to the development of TM-ILP for the treatment of locally advanced melanomas and sarcomas, with around 300 TM-ILPs perfom1ed since 1992. The resul!s of the first 24 patients with STS was prcviously publishcd in 2000 [31] . The goal of the present paper is to discuss the results of TM-ILP for STS on the long terrn. We report here that even for the most severe STS of the cxtremitics, ILP with TNF and rnclphalan is a conscrvativc trcatrncnt that can be successfully undertaken and the limb be saved from amputation or debilitating surgery in a great proportion of patients.
MATERIALS AND METHODS
Betwcen Fcbruary 1992 and March 2006. 51 patients, 27 women and 24 men, were treated in our institution for a locally advanced limb STS. Mean age was 54.9 years [range . Fifty-seven TM-JLP wcre pcrfonned, 6 patients being treated twicc.
AU patients were selected through the multidisciplinary sarcoma board of om Universily Hospital (referral center for an approximate one million population), whcre about 120 new cases of soft tissue or boue tumors are discussed each year. As our center was one of the few in Europe offering this treatment in the 1990s, only a minority of patients were coming from the usual rcfcffing population of our hospital (12 patients= 24% ). The remaining were referred from different oncologie or orthopaedic centers in Switzerland (21 patients =42%) and from other countries: France (12 patients= 24%) or Germany (5 patients= 10%).
The Faculty of Medicine's ethic commillee gave i,ts approval for the treatrnent proccdure.
The data were obtained from our Multiclisciplinary Oncology Center. For the patients not followed in our institution, referring practitioncrs were contactcd by mail or phone to collcct the data. For most of the patients, because of the distance between treatment and review, only the must important follow-up data were available, and il was gcnerally not possible to asscss daily living activities or functional and satisfaction score.
Histopathologic Diagnosis, Grading, and Staging by the sarcoma spccialist of our Pathology Department, who is a member of the French Federation of Cancer Cente1"s Sarcoma Group (FNCLCC). In three instances tissue blocs and microscopy slides were sent to the French Sarcoma Group for diagnosis review.
Tables II, IIla and IIIb display lùstopathological grading and staging of the tumors. All tumors were classified for histological grading according to the FNCLCC classification [32, 33] . There were 88% high grade tumors (Il or III). Staging was done according to TNM classification of soft tissue sarcornas [34.35] . In 65% of cases the initial stage was T2b NO MO, that is. a single large (>5 cm) deep-seated tu11101: Thcre wcre 84% stage II-IV tumors (high grade or any grade with local or distant spread). Table IV smnrnarizes the initial characteristics of the patients and tumors. Forty-six patients (90%) had tumors located on the lowcr extremity. Sarcoma presentation included 38 primary tumors (75%) 13 local recurrences (25'Yc). Forty patients (79%) presented with a single tumor and l l had multiple nodules (2 l % ). The mcan time between first symptoms and diagnosis was 22.7 months (0-128).
Patients Characteristics and Past Medical History
Eighteen patients (35o/c,) had prior surgery or their tumor: 4 were marginal (Rl) and 14 intratumoral (R2) rcscctions. Elcven patients had a surgical biopsy, 8 a core needle biopsy (most of them in our hospital. who fuvors this diagnosis method) and 2 a culaneous biopsy. In 12 cases the diagnosis mcthod was not spccified. A large amonnt of patients were referred to our center after initüù non-oncological resections for misdiagnosed soft tissue lumors, which explains the low rate of specitic oncologie diagnostic biopsy performed.
Twenty-seven patients (53%) had no past surgical or oncological treatment for their sarcorna, while prior treatments had been performed in 24 patients. 5 of them being refcned after multiple resections and 8 after multimodal treatments including surgery, chemotherapy, and radiation therapy.
Indication for TM-ILP
In 39% of patients TM-ILP was inclicatcd bccause of local spread after previous excisions. In 39%, extracompartmental location of the tumor (Fig. 1 ) or its close relationship to the neurovasculm bundle 
Contraindications
Mctastatic cliscasc docs not ncccssarily prcclude TM-ILP. There is a consensus that such patients in good pe1formance status could avoid unnecessary mutilation thanks to TM-ILP. Five patients with locoregional and thrce with distant spread were submitted to TM-ILP in our institution.
Patients with known severe arterial occlusive disease (stenosis on angiogram or Fontaine stage Ilb or more) of the impliecl limb wcre not eligible because perfusion couic! be shunted, loosing the desired antiturnoral cffect on the hypoperfused pait of the limb and increasing the sicle effects on the overperfused part of it. Patients wilh severe heart failure (NYHA class III and IV) were not eligible bccause of the inability to afford the expected transient distributive shock (see Leakage Monitoring and Barly Complications Section).
ECOG status > l, severe organ dysfonction, infection (local or systemic), immunosuppression (allograft recipients, drug-induced, disease-linked) and significant autoimmune diseuse patients were a1so not cligible for TM-ILP.
Leakage Monitoring and Early Complications
Throughout perfusion, leakage was monitored using radiolabeled albumin injected in the extrncorporeal circulation and measured in the precordium with a scintillation probe [36] . No patient suffcred lifethreate1ùng leakage. In the early post-operative phase (hours to days ), all the patients experienced some transient distributive shock due to leakagc of small amounts of TNF in the systemic circulation after discontinuation of the extracorporeiù circulation [37] . All patients were admitted in the Intensive Care Unit for al least 24 hr.
Regional toxicity was described by Wiebcrdink et al. in 1982 [38] . We used this classification to evaluate toxicity of the treatment on the perfusecl extremity and Lhe WHO classification [39] to monitor the side effects of the treatment on gencral health.
Systemic leakage, when irnpmtant, may yield hematological complications due to systemic effects of chemotherapeutic dmgs [40] . Sorne patients expeiiencecl cytopenia, with rare cases of agranulocytosis. In the present series, tlùs kind of complications dicln't generate significant consequences and wi11 not be discussed any further.
Response Assessment TM-ILP response was assessed by measuring vanatlon of the longest dimneter and necrosis estimate on monthly MRI, according to the RECIST critelia [41] . Aftcr tumor rcmnants excision up-and down-grading were then considered. depending on the amount of tumoral nccrosis dctennined at microscopie examination as described by Eggermont et al. [23] . Thus the single most important factor, that determined tumor response, was turnor cells necrosis on microscopie examination.
Resection of the Tmnor Remuants and
Complementary Treatments AH patients were reevaluated in our rnultidisciplinary Sarcorna Board. Rcsection of the tumor remnants was clone whenevc1· possible, depending on clinical response and general status of patients. Monthly MRI examinations were repeated until best tumor response was obtaincd; rcsection was then pcrformccl. cithcr in our centcr, or by the oncologie orthopacdic surgeon of the rcfcning center.
Complementary treatments (radiation therapy, chemotherapy or combined chcmo-and radiotherapy) were discusscd according to tumor grade, response to TM-ILP and resection margins mainly.
Late Complications
Due to TNF and melphalan pe1fusion, surgery and/or radiation therapy, long-lasting locoregional complications are often observed after TM-ILP. Actually, all the patients presented with some degree of skin redness or pigmentation, some amount of edema and skin atrophy. We have focused on severe long-lasting complications, including skin necrosis, ncurological complaints and othcr issues that might have notable consequences on daily living or have necessitated new treatments. As half of the patients were demi by the time ol' the review, and as most of them wcrc coming from al! parts of Switzcrland, France and Germany, it was not possible to examine them and determinc a functional Jimb score.
Limb Salvage, Local, Loco-Regional and Distant
Recurrences, Amputations and Survival
In calculation of amputation rate, primary amputations wcre those pcrforrned dircctly after TM-ILP for unsatisfactory rcsponse to treatment or local complications. Secondary amputations were those perfonnccl later, cithcr after a lornl relapse or after latc progression of an unremovcd primary tumor.
Recurrences were considered as local when they presented in or near the rcsection bec! of the prirnary tumor, for cxarnple in the samc segment (thigh, Jcg, ann, forcarrn, etc.) or cornpartment of the limb. and loco-regiomù when located in the next segment (for example skip metastases in the thigh from a primary turnor of the leg) or in the known rcgional lymph nodes of the limbs (poplitcal. ilio-inguinal, elbow, or axillary nocles). Local recurrences were always located within the perfused area. whereas loco-regional recurrences might appear within or outside the perfused area.
Metastases were considered as distant in ail other situations (controlateral Jimb, other extremity or girdle, cerebral or thoracoabdominal locations).
Statistical Methods
Confidence intervals for ail data were based on the binomial law [42] . Amputation Rate, Disease-Free Survival (DFS) and Overall Survival curves were established according to the Kaplan-Meier (K-M) methods [43] . Survival and local or distant recurrences, as we11' as disease-free interval were measured from the date of the TM-ILP. Patients still alive were considered as censored observations at the date of the last follow-up. Ail data were reviewed by our clinical cpidemiologist, who detcnnincd the K-M curves and the rccurrencc and survival rates by using the software "R" [44] . 
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Toxicity and Complications
The mean Intensive Care Unit stay was 2 days (0-11), with 4 patients staying more than 3 days.
Twclve patients (21 %) prcscntcd with scrious carly complications. of which four hacl a transient nerve palsy (Wieberdink grade 3) and one had a compartment syndrome of the thigh (grade 5) who evcntually was arnputatcd duc to ongoing scvere sciatic nervc palsy combined with extensive skin necrosis. Other severe complications included 3 patients with hematologic disorders (WHO grade 2 or more), 2 reopcrations in emcrgcncy for rctroperitoneal bleecling, one extensive tumor necrosis with early debulking after 13 days, 2 temporary renal failures, one temporary liver failure and 1 thrombocmbolic discasc, somc of thcm in the samc patient. Ail patients sustained at least a Wieberdink grade 2 local reaction (limb edema, skin redness).
Thirteen patients (23%) suffcrcd from late complications: 8 cutaneous, 7 long-lasting neurologie (comprising pain and algodystrophy), 1 articular (elbow stiffness), l orthopedic (femoral nail fatigue fracture) and one septic shock. Among 8 patients with cutaneous complications, 4 needed multiple plastic surgery procedures to cover defects, and 4 had a chronic skin ulcer. Two of them had received complementary radiation therapy.
Two patients sustained both carly and late complications. uncorrelated one with the other.
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Tumor Remnants Excision and Complementary Treatment
Following the first TM-ILP tumor remnants were resected in 33 patients (65%), while 7 (14%) had to be amputated. Ten distant en bloc rcsections (RO), 20 marginal (RI) and 3 intra-tumoral (R2) wcre performed. On six patients, because of early appearance of distant metastases, no operation was perfom1ed.
After the second TM-ILP, 1 RI, 1 R2 rcsection and 2 amputations were pe1fonned: while 2 patients were treated conservatively.
Sixteen (31 % ) patients received a complementary treatment: radiation therapy in 9, systemic chemotherapy in 3 and combined radio-and chemotherapy in 2.
Recurrence Thirty-two patients (63%) suffered from recurrence. Tcn patients had distant recurrence alone, 6 local recurrence alone and 4 locoregional recurrence alone. Eleven patients sustained both local and distant relapse (5 synchronously, 3 locally first, and 3 distantly first), and one patient had synchronous local, loco-regional and distant relapse.
Recurrence within pe1fusion area occurred in 19 patients (37%) and outside perfusion area in 25 patients (49%). 
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Seventy-seven percent of them were located in the lungs. Initial response to TM-ILP had been a CR in 6 (23% ), a PR in 11 (42% ), a NC in 4 (15%) and a PD in 5 (19%). ·
Disease-Free and Overall Survival
Mean DFS from TM-ILP was 14.9 months (2-49). Threc patients with distant metastases prior to TM-ILP were not considered. Overall survival rates al 2, 5, and 10 years were 60%, 44% and 28% respectively.
Twenty-four patients out of 51 have died (47%) with a mean overall survival of23.3 months (4-93). All patients but one died or the disease (96%).
Amputations and Limb Salvage
Following TM-ILP limb salvage was not possible in 12 patients (24%), with 7 primary and 5 secondary amputations, as shown in Figure 3 . whcre thcre is an carly steep curve co11'Csponding to the primary amputations after ILP and it is followed by a linear and not steep curve corresponding to the secondary amputations. This illustrates that the sccondary amputations wcre duc to the natural outcome of the disease not in relation with ILP.
No specific risk factors could iclentify patients who finally needed amputation (emly or Jale) in this heterogeneous group of patients. Primary amputation was clecided in 7 patients: 5 had insufficient trealment response (NC or PD), one patient lrncl u local multi-operated stalus und one patient had a compartment syndrome with complete sciatic nerve palsy. Five different histological diagnoses and ail grades were present.
Seco!ldary amputation was performed in 5 patients ( 12%,): two had an unsuceessful rcsponsc to a second TM-ILP, two patients had a diffuse local relapse and one patient, who refused excision of the prirnary tumor after TM-ILP, had a slow progressive disease during 3.5 ycars.Overall prirnary limb salvage rate was 86%, and the total limb sparing 76%.
DISCUSSION
This retrospective study is based on u selecled group of patients with a very poor prognosis (88% of the patients in this scries had a high grade and 84% an advanced staged tumor). It clemonstrates that TM- ILP is able to offer a limb sparing strategy even for the patients with the most aggressive non-rescctable soft tissue sarcoma, observed with a long-tenu follow-up more than 10 years. While comparing other publications in the literature, the present se1ies has the longcst mean follow-up (38.9 months, 4-159) with Lev-Chelouehe's study in 1999 who was referring on six desmoid tumors [45] .
It would be cliffieult to have a much longer follow-up while clealing with advaneecl high grade sareoma patients, because most of them recur ami die within a few years after trentment as presen ted in our experience with 40% death rate after 2 years. In our results 44% of patients snrvived more than 5 years. This is of notable importance, because late relapses and amputations can be observed.
In fact the amputation rate is one of the highest cvcr published in spite of the fact that 3/12 werc submittecl to a second TM-ILP. Late amputations up to 3.5 yeru-s after TM-ILP have been identified. One may speculatc that the rcal limb salvage in some cohorts is ovenatcd because of a shorter follow-up. Likewise local relapse rate (35%) is. high compared with other series, but again 5 recurrences were obscrved more than 3 years after TM-ILP. The long-tcrm recunence rate does not seem to be influenced by longer follow-up, as only 2 patients recurred more than 3 years after treatment. Lmge differences in limb salvage and local relapse can be explained by higher proportion of aggressive tumors and longer follow-up, with consequently difficulties to compare our results with others [23, 24, 26, 29, 46 ,471.
The 25'Yo complete response (CR) rate or this series is comparable to the 28% and 29% CR of the European multiccntcr study published by Eggermont et al. in 1996 and 1999 [23, 48] . the 29% CR of the Rotterdam experience with older patients or van Etten in 2003 [49] and the 24% CR in rccurrcnt sarcomas in irracliatcd fields of Grünhagcn in 2005 [50] .
CR results repm1ed by Bonvalot et al. in 2005 [51] were also higher than otirs. but they wcrc bascd on a ranclomizcd phase Ilb study (studying TNF doses) with a consistent proportion of stage lb and lia patients. Furthermore CR was considered when 90% necrosis was prcscnt on histological examination. whcrcas 98-100% nccrosis wcre required in our series f 48-511. With 42% PR. the objective response rate is 67%, which is also comparable to the aforementioned studies (57-76%).
Classical early complications related to TM-ILP (local, hemodynamic, hematological, renal, hepatic, etc.) were present in 21 %·of the
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patients. ln most of the cases they were transient, predictable and successfully managcd. They gcnerated a mean Intensive Care Unit stay of 2 days (0-11), with 4 patients staying more than 3 days. They were mainly due lo systernic TNF leakage during perfusion distinct from the so called "tourniquet effcct," as dcscribed by Christoforidis et al. in 2003 [37] . These data are not consistently different from what bas already been descrihed in the lilerature [28, 38, 39] . With lwo early re-opcrations (3.5%) for bleeding on the cannulation site, this se1ies reaches an acceptable complication rate. Scarce data in the recent literature makes a global comparison dirticult to establish. No treatment-rclatecl clcath was rcportcd.
With 23% late and long-lasting complications, this serics is also comparable to others; local consequences ofTM-lLP can be serions, as one patient needcd to be amputatcd one year after treatment becausc of a Wieberdink grade 5 complication (thigh compartmcnt syndrome and subsequent complete sciatic nerve palsy). Eight patients suffered from pennanent skin ulccr or needecl iterative surgcry to cover a cutaneous defcct. It is however difficult to distinguish bctwcen tumor-rclatcd from TM-ILP-related skin complications. It is worth mentioning that only two of the 13 patients with long-lasting complications had rcceived complcmcntary radiation therapy. Together with Olicrnan et al. [47] and Vrouenraets et al. [52] we think that complementary radiotherapy is not contraindicntecl after TM-ILP and excision of tumor remuants, as far as local healing is acquired. In order to improve postoperative ederna, we have introduced early systematic lymphatic drainage (in the !CU), mobilization therapy and mild-pressure stockings. with subjective promising results, although no objective measurements have been performed.
Tumor remnants excision was performed in 33 patients (65%) after the first TM-ILP and in two out of 6 aftcr the second one. Marginal resection (Rl) is the rule (20/34). TM-ILP often facilitates surgical resection not only because of tumor shrinkage, but also hecause the sarcoma is better delincated. The prcvious fragile thin pseuclocapsule is replaced by a thick fibrous pseudocapsule. It is constituted by the turnor response itself and by surrounding non-tumoral fibrosing tissue (Fig. 4 ) . The surgeon fine! this resistant pseuclocapsule, which en ables a safer null'ginal resection of the tumor remuant with a lower risk for positive surgical rnargins or capsule break with tumor spilling in the rcscction bed.
With 76% total limb salvage, our data are within the range of the recent literature (from 58% for Noorda et al. in 2003 [27] to 89% for Santinami el al. in 1996 [24] ). Initial TM-ILP and tumor remmml excision cven reach 86% plimary limb salvage, which is close to the best results published by Santinami et al. in 1996 [24] with 90% limb sparing for afler 15 months follow-up. As the primary lreatment end-point is amputation or debilitating surgery prcvention, wc may consider the present results as satisfactory.
Local recurrence w~1s observed in 19 patients (37%), which compares with others [25, 46] . This high rate can be cxplained on one hand by a longer mean follow-up (> 3 years) allowing la te recmrences registration and on the other hand by a higher proportion of high grade and high stage tumorn. Finally wc also get a great arnount of recuffences or disseminations in already rnulti-operated patients, who were referred to our center for TM-ILP.
In rnost of the cases local and distant recurrences occnffecl sirnultaneously. Systemic rnetastases presented first or synchronously in 68%. Ali together, a total of 26 loco-regional or distant recurrences (51 % ) wcre obscrvccl. This inclicates that a distant spreacl was probably already present by the time of TM-ILP. Actually, al! patients with recurrence had a high-grade sarcoma. It confirms that the less cliffercntiated the turnor, the more aggressive the biological behavior and the higher the risk for relapse, whatever the stage as alreacly mentioned. It confirms that local contrai does not correlate with overall survival [6] [7] [8] [9] .
Five years survival rate after TM-ILP was 44%, with 96% diseaserelated deaths. In 2003, Noorda et al. [27] reported 48% 5-year disease specific survival rate, but with 20% grade I and 41 ')!, stage l m1d Il lmnors. Other serics do not mention 5-year survival rate becausc of a shorter follow-up.
For soft tissue lirnb sarcomas lreated by classical surgery. Pisters mentioncd 76% survival after 5 ycars [53] . This corresponds to the fact that a group of patients combining less aggressive sarcomas with ail stages together have a better prognosis and cannot be compared with our series of patients, that incluclcs 88% high gracie (FNCLCC II and III) and 85% >stage IB STS. Patients who couic! afforcl an oncological sale resection were sparecl TM-ILP in our Sarcoma Board. Om series demonstrates that preservativc trcatment shoulcl be considcrcd in orcler to prevent the remaining patients with a poor prognosis from mutilation.
Limitations of this retrospcctivc stucly inclucle difficultics for collecting data. Seventy-six percent of patients were coming from outside the referring population of our University Hospital and more than half had died by the timc the data were collccted. Following the publishcd review of the first 24 patients (1992-1998) [31] , no database or prospective follow-up were available by the lime the prcsent review was restarted. Another limitation was the impossibility to evaluate any functional outcome or impact on claily living, which should ideally be part in a study evalualing a local treatment strategy, but this aspect of TM-ILP was thoroughly describecl by Vrouenraets et al. in 1999 [46] : he demonstrated 25% global limb atrophy and 40% restricted ankle extension after 48 months.
The present stucly is a rctrospective rcview of aÙ the STS trcatecl by TM-ILP in our center. lt is very heterogeneous when reg<mling 10 clifferent histopathological diagnoses, 11 different TNM and 6 differcnt stages togethcr in the samc serics. Howcvcr it is homogeneous and different from other series in that there are almost only high grades (Il and III) and high stages (lia-IV). We might have been more selective and exclucle the lower gracies and stages in order to cletermine the outcome of the treatment only for high grade and high stage tumors, considering that indications to TM-ILP do not depend on the histopathologic characteristics of the tumors. However considering that al! patients presented criteria of irresectability, we decided not to exclucle any patient frorn the review. It is important in thal TM-ILP offers long-tenn perspectives of limb salvage in all patients with an advanced STS of an extrernity, whatcver the prognosis. It is not dedicated only to condemned patients for whom an amputation would Jvuma/ of Surgica/ Oncolugy significantly worsen the quality oflife during the last months or years of thcir existence. CONCLUSION TM-ILP is a procedure with a high immecliate and late complications rate. Long-lerm resulls show that, even for the mosl severe soft tissue sarcomas of the extremities (88% high grade and 84% advanced stage tumors in the present series), this conservative treatment can be successfully undertaken and the limb be saved on the long tenn from amputation or debilitating surgery in thrce quarters of the patients.
